Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Genotropin (somatropin by Quarter
Genotropin (somatropin — growth hormone) — Worldwide operational (constant-currency) YoY (%) (%)
Pfizer Genotropin (somatropin: -15.0% in Q2 2026, down 5.0 pts from a year earlier.
Latest, Q2 2026
-15.0%
Period ended Jun 28, 2026
Change on a year earlier
-5.0 pts
-10.0% in Q2 2025
History
34 quarters
Since Q4 2017
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
“|| Genotropin | 94 | 106 | (11%) | (15%) | 2 | 18 | (89%) | 92 | 89 | 4% | —”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Genotropin (somatropin (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/genotropin-oper-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.